Literature DB >> 3094443

Comparative clinical efficacy of single oral doses of cefuroxime axetil and amoxicillin in uncomplicated gonococcal infections.

I W Fong, W Linton, M Simbul, N A Hinton.   

Abstract

Cefuroxime axetil (1.5 g) was compared with amoxicillin (3 g), both given as a single oral dose combined with probenecid (1 g) for the treatment of uncomplicated gonorrhea. Of 60 evaluable patients receiving amoxicillin, 55 (91.7%) were cured, whereas 55 (96.5%) of the 57 patients receiving cefuroxime axetil were cured (P greater than 0.1). Both drugs were well tolerated.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3094443      PMCID: PMC180542          DOI: 10.1128/AAC.30.2.321

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  National gonorrhea therapy monitoring study: in vitro antibiotic susceptibility and its correlation with treatment results.

Authors:  H W Jaffe; J W Biddle; C Thornsberry; R E Johnson; R E Kaufman; G H Reynolds; P J Wiesner
Journal:  N Engl J Med       Date:  1976-01-01       Impact factor: 91.245

2.  Dose response evaluation of cefuroxime in the treatment of gonorrhœa in male and female patients.

Authors:  J D Price; J L Fluker
Journal:  Proc R Soc Med       Date:  1977

3.  Cefuroxime and post-gonococcal urethritis.

Authors:  W Fowler; G Rahim
Journal:  Proc R Soc Med       Date:  1977

4.  Single oral dose ampicillin-probenecid treatment of gnorrhea in the male.

Authors:  P A Kvale; T F Keys; D W Johnson; K K Holmes
Journal:  JAMA       Date:  1971-03-01       Impact factor: 56.272

5.  Cefuroxime - a new cephalosporin antibiotic.

Authors:  C H O'Callaghan; R B Sykes; D M Ryan; R D Foord; P W Muggleton
Journal:  J Antibiot (Tokyo)       Date:  1976-01       Impact factor: 2.649

6.  [The spread of penicillinase-forming gonococci in Amsterdam].

Authors:  R A Coutinho; F Jansen Schoonhoven; M C Ansink-Schipper; G A de Koning; D Tio
Journal:  Ned Tijdschr Geneeskd       Date:  1982-01-30

7.  Single-dose oral therapy for uncomplicated gonorrhea: comparison of amoxicillin and ampicillin given with and without probenecid.

Authors:  W W Karney; M Turck; K K Holmes
Journal:  J Infect Dis       Date:  1974-06       Impact factor: 5.226

8.  Pharmacokinetics and tolerance of cefuroxime axetil in volunteers during repeated dosing.

Authors:  D K Sommers; M Van Wyk; P E Williams; S M Harding
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

9.  Treatment of penicillin-resistant Neisseria gonorrhoeae with oral norfloxacin.

Authors:  S R Crider; S D Colby; L K Miller; W O Harrison; S B Kerbs; S W Berg
Journal:  N Engl J Med       Date:  1984-07-19       Impact factor: 91.245

10.  Single-dose treatment of gonococcal urethritis in males: evaluation of procaine penicillin, ampicillin and spectinomycin.

Authors:  R W Mitchell; H G Robson
Journal:  Can Med Assoc J       Date:  1974-01-19       Impact factor: 8.262

View more
  5 in total

Review 1.  Cefuroxime axetil: an updated review of its use in the management of bacterial infections.

Authors:  L J Scott; D Ormrod; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Cephalosporin-probenecid drug interactions.

Authors:  G R Brown
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

3.  Clinical comparison of single-oral-dose cefuroxime axetil and amoxicillin with probenecid for uncomplicated gonococcal infections in women.

Authors:  L M Baddour; R S Gibbs; G Mertz; D M Cocchetto; R C Noble
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

Review 4.  Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C M Perry; R N Brogden
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

5.  Cefuroxime axetil (ceftin): a brief review.

Authors:  R D Leder; D S Carson
Journal:  Infect Dis Obstet Gynecol       Date:  1997
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.